SAN FRANCISCO, Feb. 8 /PRNewswire/ -- Synarc, Inc. announced today that Kenneth G. Faulkner, Ph.D. has rejoined the company as Vice President of Business Development.
Dr. Faulkner is a co-founder of Synarc, the world’s largest dedicated provider of centralized imaging and molecular marker services for clinical trials. In his new role, he will be responsible for leading Synarc’s strategic alliances and expansion into new therapeutic areas. For the past five years, Dr. Faulkner has been the Chief Scientist for GE Healthcare in the Lunar Bone Densitometry division located in Madison, Wisconsin. Prior to joining GE Healthcare, he directed the osteoporosis service for Synarc until 2001. He received his Ph.D. from the Biomedical Engineering Program at the University of California, Berkeley and San Francisco and was a faculty member of the Department of Radiology at the University of California, San Francisco, until 1992. At that time, he moved to Portland, Oregon where he directed the bone densitometry central laboratory at the Oregon Osteoporosis Center, which he joined Synarc in 1998. Dr. Faulkner has published more than 75 papers related to bone densitometry, focused on the use of bone densitometry for the prevention and treatment of osteoporosis.
“I am thrilled to rejoin the Synarc team,” said Dr. Faulkner. “There are many opportunities to expand our business beyond our traditional markets. In the coming year, we intend to expand our collaborations with academic centers, industry partners, and pharmaceutical companies. Synarc is in a unique position to bridge the gap between these key players and bring new therapies to the clinical market.”
Gary Velasquez, President and CEO of Synarc commented, “We are extremely pleased to have someone with remarkable caliber as an addition to our management team. Ken’s scientific experience and knowledge of the business will make a tremendous impact and help the company expand into new therapeutic areas.”
Synarc, Inc. is the world’s largest dedicated provider of centralized imaging and molecular marker services for clinical trials. Synarc’s advanced capabilities enable pharmaceutical industry clients to accelerate clinical trials and decrease the time, uncertainty and cost of drug development. The company has eight offices in the U.S., Europe and Asia (San Francisco, Portland, Boston, Copenhagen, Lyon, Paris, Hamburg and Beijing).
Joy Valderrama
Marketing & Sales Specialist
+1-415-817-8919
Synarc, Inc.
CONTACT: Joy Valderrama, Marketing & Sales Specialist of Synarc, Inc.,+1-415-817-8919
Web site: http://www.synarc.com/
